SPDR S&P Biotech ETF (XBI) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
Benzinga13:00 ET
Market Whales and Their Recent Bets on AMGN Options
BenzingaJul 25 11:06 ET
This Is What Whales Are Betting On Gilead Sciences
BenzingaJul 25 11:06 ET
Actinium Wins FDA Nod to Conduct Clinical Trial for Radiotherapy
Seeking AlphaJul 25 10:29 ET
AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
BenzingaJul 25 10:18 ET
Cerevel Ticks Higher as AbbVie Says It Expects Deal to Close Soon
Seeking AlphaJul 25 09:27 ET

Comments

Moomoo News AU

Jul 10 04:25

Columns Australia's H2 2024 investment landscape: how to seize market opportunities?

Jinta Hong, CFA
Background
As we enter the second half of 2024, the global financial landscape remains dynamic, influenced by international relations and economic policies. While major markets like the US, Japan, India, and parts of Europe have seen significant growth, Australia has faced challenges such as inflation and weak Chinese economic performance. The $S&P/ASX 200(.XJO.AU)$ index reached a historic peak in April ...

+7

2024 half-year recap: Tell us your trading story

82

7

Fake BNF

Jun 25 08:42

$Ginkgo Bioworks(DNA.US)$ smth happened to this... 0.1 soon
It does not follow the XBI and Russell 2000 up trend for this period of time. Meaning market drops, it drops. Market ups, it still drop. Gonna cut off from my side

5

Shaaaw

Jun 25 07:07

Here’s why I think that $MRK buys $JANX soon.

$Merck & Co(MRK.US)$ on the prowl for acquisitions up to $15 billion.
$Merck & Co(MRK.US)$ already has an active partnership with $Janux Therapeutics(JANX.US)$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF(XBI.US)$ in which $Merck & Co(MRK.US)$ already has a seat at the table.
$Merck & Co(MRK.US)$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...

+1

9

Kopikarp

Jun 20 10:08

Bristol-Myers Squibb (BMY) - Options Strategy

Background and Recent Performance
$Bristol-Myers Squibb(BMY.US)$ is a global biopharmaceutical company known for its innovative treatments in oncology, immunology, and cardiovascular diseases. Over the past year, BMY has faced some challenges, with its stock price nearing its 52-week low. As of June 20, 2024, the stock is trading at $40.795, which is close to its 52-week low of around $40.00.
$Bristol-Myers Squibb(BMY.US)$
Despite recent performance s...

TA Challenge: Are you a left-side or right-side trader?

15

Shaaaw

May 13 03:31

Short Interest of Life Sciences Companies at a High Point.
Interesting list of name for the incoming CPI..
$Novavax(NVAX.US)$ $SPDR S&P Biotech ETF(XBI.US)$ $S&P 500 Index(.SPX.US)$

3

XBI SPDR S&P Biotech ETF

Trade Overview

Capital Trend

News

Comments